Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients locally advanced, metastatic, or recurrent transitional cell carcinoma of the urothelium.
Urologic Neoplasms
DRUG: S-8184 Paclitaxel Injectable Emulsion|DRUG: Experimental Arm: TOCOSOL Paclitaxel
Objective response rate; time to disease progression; duration of response; survival; toxicities, After all patients completed treatment
To determine time to disease progression, After all patients have completed treatment
The goals of this study are to determine the objective response rate, to determine time to disease progression, duration of response, and survival, and to identify the maximum tolerated weekly dose and principal toxicities of S-8184 in this patient population.